The Archives of Internal Medicine published the results of a study of Harvard Medical School comparing Avandia (rosiglitazone, GlaxoSmithKline) to Actos (pioglitazone, Eli Lilly) using the database of almost thirty thousand elderly people with diabetes over a 5 year period. About 50% of the patients were treated with rosiglitazone and 50% were taking pioglitazone. Death rates were 15% higher among patients treated with rosiglitazone, compared to those taking pioglitazone, and the incidence of congestive heart failure was 13% higher.